Turning genes into medicines-what have we learned from gene therapy drug development in the past decade?
- PMID: 33199678
- PMCID: PMC7669843
- DOI: 10.1038/s41467-020-19507-0
Turning genes into medicines-what have we learned from gene therapy drug development in the past decade?
Abstract
Gene and cell therapy products approved over the past decade in Europe and North America have provided new therapeutic options for single gene disorders and for hematologic malignancies. Lessons learned, and limitations identified, are reviewed.
Conflict of interest statement
The author declares the following competing interests: Formerly employed by and held equity in Spark Therapeutics (2014–2020); member of the Board of Directors, CRISPR Therapeutics (2019–present).
Figures
References
-
- Mendell, J. R. et al. Single dose gene replacement therapy for spinal muscular atrophy. N. Engl. J. Med.377, 1713–1722 (2017). - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
